ABSTRACT
Cranial magnetic resonance imaging (MRI) examinations were performed in 419 patients with type 2 diabetes mellitus (T2DM) from June to December 2016.The brain white matter lesions were defined by white matter hyperintensity (WMH) in MRI,which was detected in 380 cases (WMH group) and not detected in 39 cases (non-WMH group).The Montreal Cognitive Assessment (MoCA) was used to evaluate the cognitive function.The study showed that there were significant differences in the duration of diabetes,the proportion of hypertension,total cholesterol (TC) and MoCA scores between the two groups (all P＜0.05).The age,duration of diabetes,hypertension and glyclated hemoglobin (HbA1c) were significantly correlated with white matter lesions(OR=1.157,1.116,5.184,1.128;P＜0.05);and the white matter lesions,age,and body mass index (BMI) were significantly correlated with cognitive dysfunction in diabetic patients (OR=2.137,1.175,1.247;P＜0.05).The study result indicates that control of white matter lesions may prevent and improve cognitive dysfunction in T2DM patients.
ABSTRACT
Objective To explore the effect of simvastatin and atorvastatin on the level of p 27 protein in mesangial cells of rat under high glucose .Methods Cultured rat mesangial cells in vitro were divided into four groups :normal glucose(5 .6 mmol/L glu-cose) ,high glucose(30 mmol/L glucose) ,high glucose(30 mmol/L glucose) plus simvastatin(10 μmol/L) ,high glucose(30mmol/L glucose) plus atorvastatin(10 μmol/L) .After treatment for 24 ,48 ,72 120 hours ,the cells were collected .The protein level of p27 was detected by Western blotting and the mRNA level of p27 was detected by RT-PCR .Results Compared to the normal glucose group ,the levels of p27 protein and mRNA in the high glucose group had a significant increase(P<0 .05) .Compared to the high glucose group ,the level of p27 protein and mRNA in the high glucose plus simvastatin or atorvastatin group both had a significant decrease(P<0 .05) .Conclusion By modulating the expression of P27 in mesangial cells ,statins could become the independent lipid-decreasing drug to prevent kidney .